Alumis Inc (ALMS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alumis Inc (ALMS) has a cash flow conversion efficiency ratio of -0.180x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-81.50 Million) by net assets ($452.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Alumis Inc market cap and net worth for the company's overall valuation and market capitalisation.
Alumis Inc - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Alumis Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alumis Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alumis Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Alumis Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NorthWest Healthcare Properties Real Estate Investment Trust
TO:NWH-UN
|
0.037x |
|
Gallant Micro Machining Co Ltd
TWO:6640
|
0.040x |
|
Camelot Electronics Technology Co. Ltd. A
SHE:301282
|
N/A |
|
BTS Group Holdings Public Company Limited
BK:BTS
|
0.025x |
|
BrightView Holdings
NYSE:BV
|
0.026x |
|
Talon Metals Corp
TO:TLO
|
-0.005x |
|
Penguin Solutions, Inc.
NASDAQ:PENG
|
0.051x |
|
Beijing Jingwei Hirain Technologies Co. Ltd. A
SHG:688326
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Alumis Inc (2022–2025)
The table below shows the annual cash flow conversion efficiency of Alumis Inc from 2022 to 2025. View Alumis Inc (ALMS) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $301.30 Million | $-369.52 Million | -1.226x | -25.06% |
| 2024-12-31 | $260.10 Million | $-255.08 Million | -0.981x | -355.98% |
| 2023-12-31 | $-339.26 Million | $-129.97 Million | 0.383x | -30.56% |
| 2022-12-31 | $-195.24 Million | $-107.72 Million | 0.552x | -- |
About Alumis Inc
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment o… Read more